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Metastatic dissemination of cancer cells to local and distant
sites such as bone requires a complex interaction of cancer cells
with their surrounding microenvironment to allow invasion, im-
mune evasion and spread via the vascular or lymphatic systems.
The tumour microenvironment is composed of an array of cells
embedded in a complex extracellular matrix (ECM) (Fig. 1). The
predominant cell type of the tumour microenvironment, the ﬁ-
broblast, becomes corrupted by cues derived from malignant cells
and other cells present in the tumour stroma to become cancer-
associated ﬁbroblasts (CAF). The presence of CAF correlates with
poor disease outcome in a number of tumours, leading to the
suggestion that they may present a viable novel therapeutic target.
In this review we summarise the roles of CAF in the metastatic
cascade and focus on the emerging understanding of their con-
tribution to dissemination and growth of tumours in bone.2. Cancer associated ﬁbroblasts – bad neighbours in the tu-
mour microenvironment
Malignant tumours grow and spread by corrupting the sur-
rounding stroma, composed of cells such as ﬁbroblasts, endothelial
cells, and immune cells (Fig. 1), to encourage cancer cells to pro-
liferate, evade the host’s immune system, and metastasise. There
exists considerable evidence highlighting the prognostic im-
portance of various components of the modiﬁed cancer micro-
environment, including cancer-associated ﬁbroblasts (CAF) [1–3].
CAF are the most abundant cell type in the tumourx.doi.org/10.1016/j.jbo.2016.03.008
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ging due to their heterogeneity [4]. CAF express mesenchyme
speciﬁc markers such as ﬁbroblast activating protein (FAP), ﬁbro-
blast speciﬁc protein 1 (FSP1/S100A4), vimentin, platelet derived
growth factor receptors, podoplanin and the most commonly used
marker, alpha smooth muscle actin (α-SMA) [5], but many of the
markers used to identify them are expressed by other cell types;
for example podoplanin is found in lymphatic vessels, as well as
some cancer cells or, platelet-derived growth factor receptor β
(PDGFRβ) is expressed by pericytes . Some of the heterogeneity
observed in CAF populations may result from subpopulations
arising from different origins; resident ﬁbroblasts, mesenchymal
stem cells, ﬁbrocytes, stellate cells (pancreas, liver), Kuppfer cells
(liver), endothelial cells, smooth muscle cells, myoepithelial cells
(breast), pericryptal myoﬁbroblasts (gastrointestinal tract) have all
been demonstrated to give rise to CAF [6,7]. It is notable, however,
that the heterogeneity of CAF is generally accepted to arise not
from genomic changes (ie alterations in DNA sequence) but rather
from epigenetic and other modiﬁcations of gene expression. This is
signiﬁcant as the genomic stability of CAF make them less likely to
acquire resistance to therapy frequently encountered when phar-
macologically targeting genomically unstable cancer cells, and
therefore an attractive target for intervention [4].
The presence of an inﬂammatory inﬁltrate is associated with
poor prognosis in a number of malignancies, including those with
a predilection for metastasis to bone. CAFs are capable of pro-
moting, and maintaining an inﬂammatory environment by re-
cruiting immune cells; in particular monocyte/macrophage
through secretions of cytokines and chemokines. Recruited mac-
rophages are known to polarise towards mostly the tumour pro-
moting M2 type which encourage angiogenesis, immune sup-
pression and metastasis. Evidence demonstrates that CAFs recruit
monocytes mostly through CCL2-CCR2 in breast cancer and mel-
anoma, and CD68þ macrophages through CXCL14 in prostateCC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Cancer associated ﬁbroblasts in the tumour microenvironment. Schematic depicting the major components of the tumour microenvironment, including cancer cells
(pink), cancer associated ﬁbroblasts (blue), adipocytes (yellow), granulocytes (grey), pericytes (brown), macrophages (purple) and T-cells (dark pink).
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CD14þCD1a monocytes to macrophages . CAFs also recruit mast
cells through secreting IL-6, and T lymphocytes via CXCL9, CXCL10,
and CXCL12 which promote angiogenesis and modulate immune
responses to tumour cells .
One of the major roles of normal ﬁbroblast is to secrete com-
ponents of extracellular matrix (ECM) and this property is retained
in CAFs, however the ECM secreted is altered to support tumour
growth and invasion. Many tumours are surrounded by a desmo-
plastic stroma; that is, one rich in collagen, ﬁbronectin, and other
ECM components, which has been associated with poor prognosis
[9]. Early breast tumours show ECM stiffening due to cross linking
of collagen catalysed by lysyl oxidase (LOX) expressed by CAFs, and
stiffer ECM is known to promote aggressive growth in hypoxic
cancer cells [9]. CAFs have an enhanced expression of ﬁbronectin
which has demonstrated a role in cell adhesion and increased
metastatic potential in Lewis lung cancer, ovarian cancer, and
melanoma [10]. Their role in maintaining ECM homeostasis makes
ﬁbroblasts an important component of mechanisms regulating
tissue mechanics. Changes in ECM stiffness are frequently ob-
served in the tumour microenvironment and are known to inﬂu-
ence tumour cell and ﬁbroblast phenotype (reviewed in Bonnans
et al. [11]). Wong and colleagues demonstrated activation of focal
adhesion kinase (FAK) in ﬁbroblasts by mechanical forces leading
to secretion of CCL2, consequently recruiting macrophages [12].
Evidence also exists supporting knockdown of FAK in CAFs in oral
squamous cell carcinoma inhibited metastasis by minimizing CCL2
secretion [13]. The immune cells recruited as a result secrete cy-
tokines and MMPs and may further modulate the ECM to promote
metastasis.
CAF in primary tumours also secrete a variety of factors that can
directly inﬂuence the behavior of cancer cells and encourage dis-
tant metastasis. For example, stromal derived factor 1 (SDF-1/
CXCL12), which interacts with cancer cells through CXCR4 indu-
cing tumour growth and metastasis (including to bone) [14]. Other
factors released by CAF, such as epidermal growth factor receptorPlease cite this article as: P. Prajapati, D.W. Lambert, Cancer-associate
Journal of Bone Oncology (2016), http://dx.doi.org/10.1016/j.jbo.2016(EGFR) ligands also promote tumour growth and metastasis by
interacting directly with cancer cells [15]. Extracellular vesicles
(EV, frequently erroneously referred to generically as exosomes)
are also reported to play a role in the paracrine signaling between
CAF and cancer cells [16], possibly through the delivery of micro-
RNA which inﬂuence speciﬁc gene expression proﬁles in recipient
cells [17].3. The malignant stroma – conspirator in bone metastasis?
Bone metastasis is a common and often devastating feature of
several cancers; some subtypes of breast cancer and prostate
cancer in particular show a predilection for dissemination to bone
[18]. Once present in the bone microenvironment, malignant cells
can stimulate bone destruction or formation leading to pain,
fracture, hypercalcaemia, and spinal cord compression. The de-
terminants of bone-tropic metastatic dissemination are poorly
understood, but it is becoming evident that the primary tumour
microenvironment may play a key role. CAF in particular are
known to secrete elevated levels of several cytokines and growth
factors found in the bone marrow microenvironment, suggesting
that the primary stroma may be able to select for cancer cells able
to thrive in bone. This hypothesis was given credence by the work
of Zhang et al., who provided evidence that CAF in the primary
tumour microenvironment of an aggressive and bone-tropic sub-
class of triple negative (TN; negative for estrogen receptor, pro-
gesterone receptor and HER2 ampliﬁcation) breast cancers secrete
factors such as IGF-1 and CXCL12 [19]. These cytokines select for
cancer cells with high src activity and PI3K-Akt signaling which
subsequently thrive in the bone microenvironment (illustrated in
Fig. 2). In prostate cancer, TGFβ–dependent signals such as CXCL1
and CXCL16 derived from stromal CAF have been shown to pro-
mote growth of metastatic lesions in bone [20].
In addition to CAF in the primary tumour microenvironment, it
is tempting to speculate that ﬁbroblasts within the bone itself mayd ﬁbroblasts – Not-so-innocent bystanders in metastasis to bone?
.03.008i
src
src
src
src
IGF1 CXCL12
IGF1
CXCL12
CXCL12
CXCL12
IGF1
Fibroblasts
Osteoblasts
Metastatic cancer
cells
Osteoclasts
Blood vessel
Bone matrix
IGF1
IGF1
IGF1
CXCL12
CXCL12
CXCL12
IGF1
Cancer cell with
high src
IGF1/CXCL12
secreting CAF
Primary tumour
Bone
Fig. 2. Cancer associated ﬁbroblasts can select cancer cells primed to thrive in the bone environment. Schematic illustrating the ability of a subset of CAF associated with
the primary tumour (blue cells in the stroma) to select a sub-population of cancer cells with high src activity (brighter pink primary cancer cells), secreting a high level of
IGF-1 and CXCL12, cytokines also present at high levels in bone. These cancer cells with high src activity are able to metastasise to and thrive in this bone environment [19].
P. Prajapati, D.W. Lambert / Journal of Bone Oncology ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 3play a role in the establishment of metastatic deposits. Fibroblasts
form a major component of the bone marrow stroma and regulate
haematopoiesis by secreting a range of cytokines, including those
known to be involved in metastatic growth in bone [21]. Bone
remodeling provoked by tumour growth (particularly in osteolytic
lesions) causes the release of proteins such as TGFβ that may ac-
tivate ﬁbroblasts to secrete cytokines favouring further tumour
growth [4,22].4. Future perspectives
The tumour microenvironment is emerging as a key con-
tributor to cancer metastasis to distant sites, including bone. Ac-
cordingly, the cells of the microenvironment, such as CAF, are in-
creasingly recognized as a potential therapeutic target and prog-
nostic biomarker. There remain, however, a number of barriers toPlease cite this article as: P. Prajapati, D.W. Lambert, Cancer-associate
Journal of Bone Oncology (2016), http://dx.doi.org/10.1016/j.jbo.2016translating this into the clinic. These include the complex het-
erogeneity of the CAF phenotype and the limited of understanding
of the nature of CAF-derived signals contributing to metastasis.
Greater understanding of CAF biology of bone-tropic tumours may
identify markers which could be used for patient stratiﬁcation,
prognostics and as direct therapeutic targets to reduce metastasis
to bone.Conﬂicts of interest
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